IN2014MN01756A - - Google Patents
Info
- Publication number
- IN2014MN01756A IN2014MN01756A IN1756MUN2014A IN2014MN01756A IN 2014MN01756 A IN2014MN01756 A IN 2014MN01756A IN 1756MUN2014 A IN1756MUN2014 A IN 1756MUN2014A IN 2014MN01756 A IN2014MN01756 A IN 2014MN01756A
- Authority
- IN
- India
- Prior art keywords
- compounds
- disclosed
- therapy
- thereofs
- subtype
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1756MUN2014 IN2014MN01756A (enExample) | 2012-03-06 | 2013-02-22 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN237KO2012 | 2012-03-06 | ||
| IN236KO2012 | 2012-03-06 | ||
| IN235KO2012 | 2012-03-06 | ||
| IN1307KO2012 | 2012-11-12 | ||
| PCT/IB2013/051455 WO2013132380A1 (en) | 2012-03-06 | 2013-02-22 | Thiazole derivatives as alpha 7 nachr modulators |
| IN1756MUN2014 IN2014MN01756A (enExample) | 2012-03-06 | 2013-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01756A true IN2014MN01756A (enExample) | 2015-07-03 |
Family
ID=54261190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1756MUN2014 IN2014MN01756A (enExample) | 2012-03-06 | 2013-02-22 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9388196B2 (enExample) |
| EP (1) | EP2822946A1 (enExample) |
| AU (1) | AU2013229177B2 (enExample) |
| CA (1) | CA2866015A1 (enExample) |
| IN (1) | IN2014MN01756A (enExample) |
| NZ (1) | NZ629453A (enExample) |
| SG (1) | SG11201405239WA (enExample) |
| WO (1) | WO2013132380A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY34832A (es) * | 2012-05-31 | 2013-12-31 | Phenex Pharmaceuticals Ag | TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda) |
| WO2014072957A1 (en) * | 2012-11-12 | 2014-05-15 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| AU2014229300A1 (en) | 2013-03-13 | 2015-06-11 | Lupin Limited | Pyrrole derivatives as alpha 7 nAChR modulators |
| TW201446243A (zh) | 2013-06-03 | 2014-12-16 | Lupin Ltd | 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑 |
| WO2014203150A1 (en) | 2013-06-17 | 2014-12-24 | Lupin Limited | Pyrrole derivatives as alpha 7 nachr modulators |
| SG11201610975RA (en) * | 2014-07-03 | 2017-01-27 | Celgene Quanticel Res Inc | Inhibitors of lysine specific demethylase-1 |
| ES2764660T3 (es) | 2014-12-16 | 2020-06-04 | Axovant Sciences Gmbh | Compuestos de amida de quinuclidina sustituida geminal como agonistas de receptores alfa-7 nicotínicos de acetilcolina |
| WO2016201096A1 (en) | 2015-06-10 | 2016-12-15 | Forum Pharmaceuticals, Inc. | Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors |
| EP3325473A4 (en) | 2015-07-22 | 2019-06-26 | The Royal Institution for the Advancement of Learning / McGill University | Compounds and uses thereof in the treatment of cancer and other medical disorders |
| HK1253295A1 (zh) | 2015-08-12 | 2019-06-14 | Axovant Sciences Gmbh | 作为7-烟碱乙酰胆碱受体的激动剂的偕取代的氨基苯并异恶唑化合物 |
| CN108101860B (zh) * | 2018-02-08 | 2021-11-23 | 苏州敬业医药化工有限公司 | 顺式-2，6-二甲基吗啉的制备方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3953596A (en) | 1973-06-14 | 1976-04-27 | Ici United States Inc. | 8-Oxa-3-azabicyclo(3.2.1)octane analgesic compositions and method of alleviating pain in animals |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| AU3201095A (en) * | 1994-07-27 | 1996-02-22 | G.D. Searle & Co. | Substituted thiazoles for the treatment of inflammation |
| US5608082A (en) | 1994-07-28 | 1997-03-04 | Agouron Pharmaceuticals, Inc. | Compounds useful as antiproliferative agents and GARFT inhibitors |
| JP4290872B2 (ja) | 1997-09-12 | 2009-07-08 | メルク フロスト カナダ リミテツド | シクロオキシゲナーゼ−２阻害薬としての２，３，５−トリ置換ピリジン類 |
| TWI262917B (en) | 2002-02-01 | 2006-10-01 | Dainippon Sumitomo Pharma Co | 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same |
| FR2840303B1 (fr) | 2002-05-31 | 2005-07-15 | Rhodia Chimie Sa | Procede d'arylation ou de vinylation ou d'alcylynation d'un compose nucleophile |
| SE0201938D0 (sv) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New process |
| DE10244810A1 (de) | 2002-09-26 | 2004-04-08 | Bayer Ag | Neue Morpholin-überbrückte Indazolderivate |
| US7129235B2 (en) | 2003-07-11 | 2006-10-31 | Abbott Laboratories | Amides useful for treating pain |
| US7442805B2 (en) | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
| GB0403038D0 (en) | 2004-02-11 | 2004-03-17 | Novartis Ag | Organic compounds |
| CA2561639A1 (en) | 2004-03-29 | 2005-10-06 | Neurosearch A/S | Novel urea derivatives and their medical use |
| ITTO20040264A1 (it) | 2004-04-28 | 2004-07-28 | Rotta Res Lab Spa | Nuovi derivati pirrolici ad attivita' angiotensina-ii antagonista |
| CA2579886A1 (en) | 2004-09-09 | 2006-03-16 | Chugai Seiyaku Kabushiki Kaisha | Novel imidazolidine derivative and use thereof |
| US20060142349A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Inc | Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor |
| JP2008530171A (ja) | 2005-02-16 | 2008-08-07 | ノイロサーチ アクティーゼルスカブ | 新規なジアザ二環系アリール誘導体及びそれらの医療上の使用 |
| FR2885616B1 (fr) | 2005-05-12 | 2007-06-22 | Servier Lab | Nouveaux derives de phenylpyridinylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20070032531A1 (en) | 2005-08-04 | 2007-02-08 | Apogee Biotechnology Corporation | Sphingosine kinase inhibitors and methods of their use |
| ES2632940T3 (es) | 2005-09-13 | 2017-09-18 | Janssen Pharmaceutica Nv | Derivados de tiazol sustituidos con 2-anilin-4-arilo |
| ES2452031T3 (es) | 2006-02-03 | 2014-03-31 | Eli Lilly & Company | Compuestos y procedimientos para modular receptores FX |
| WO2007093602A1 (en) | 2006-02-16 | 2007-08-23 | Neurosearch A/S | Enantiopure quinuclidinyloxy pyridazines and their use as nicotinic acetylcholine receptor ligands |
| JO3019B1 (ar) | 2006-04-19 | 2016-09-05 | Janssen Pharmaceutica Nv | ثلاثي مستبدل 4،2،1-ثلاثي زولات |
| BRPI0712667A2 (pt) | 2006-06-27 | 2012-09-04 | Abbott Lab | derivados do pirrol e seus métodos de uso |
| US7683084B2 (en) | 2006-06-27 | 2010-03-23 | Abbott Laboratories | Thiazoline and oxazoline derivatives and their methods of use |
| WO2008057336A2 (en) | 2006-11-02 | 2008-05-15 | Merck & Co., Inc. | Heterocyclyl-substituted anti-hypercholesterolemic compounds |
| US20080287479A1 (en) | 2006-12-20 | 2008-11-20 | Pfizer Inc | Inhibitors of serine palmitoyltransferase |
| KR20100046179A (ko) | 2007-08-08 | 2010-05-06 | 뉴로서치 에이/에스 | 니코틴성 아세틸콜린 수용체의 조절제로서 유용한 신규한 １，２，３－트리아졸 유도체 |
| GB0718735D0 (en) | 2007-09-25 | 2007-11-07 | Prolysis Ltd | Antibacterial agents |
| EP2207540B1 (en) | 2007-10-04 | 2014-02-26 | F. Hoffmann-La Roche AG | Cyclopropyl aryl amide derivatives and uses thereof |
| EP2205573B1 (en) | 2007-10-04 | 2013-10-23 | F. Hoffmann-La Roche AG | Tetrazole-substituted aryl amide derivatives and uses thereof |
| JO2784B1 (en) | 2007-10-18 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | 5,3,1 - Triazole substitute derivative |
| CN102066343B (zh) | 2008-03-19 | 2013-12-04 | 詹森药业有限公司 | 作为烟碱乙酰胆碱受体调节剂的三取代1，2，4-三唑类 |
| US7786171B2 (en) | 2008-04-04 | 2010-08-31 | Abbott Laboratories | Amide derivatives as positive allosteric modulators and methods of use thereof |
| JP2011516598A (ja) | 2008-04-17 | 2011-05-26 | グラクソ グループ リミテッド | ニコチン性アセチルコリン受容体サブタイプアルファ−７１のモジュレータとしてのインドール |
| KR20110007234A (ko) | 2008-05-09 | 2011-01-21 | 얀센 파마슈티카 엔.브이. | 아세틸콜린 수용체 조절제로서의 삼치환된 피라졸 |
| EP2387575B1 (en) | 2009-01-15 | 2013-09-04 | Anvyl, LLC | Alpha7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
| WO2010120854A1 (en) | 2009-04-15 | 2010-10-21 | Glaxosmithkline Llc | Chemical compounds |
| WO2010130768A1 (en) | 2009-05-14 | 2010-11-18 | Neurosearch A/S | Novel 1,4-diaza-bicyclo[3.2.1]octane derivatives useful as nicotinic acetylcholine receptor modulators |
| TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α７活化劑之用途 |
| JO3078B1 (ar) | 2009-11-27 | 2017-03-15 | Janssen Pharmaceutica Nv | مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة |
| BR112013019893A2 (pt) | 2011-02-03 | 2016-10-11 | Lupin Ltd | derivados de pirrol usados como moduladores de alfa7 nachr |
| CA2826792A1 (en) | 2011-02-23 | 2012-08-30 | Lupin Limited | Heteroaryl derivatives as alpha7 nachr modulators |
| JP2014509641A (ja) | 2011-03-31 | 2014-04-21 | ルピン・リミテッド | アルツハイマー病やパーキンソン病などの神経変性疾患の治療に用いられるニコチン性アセチルコリン受容体モジュレータとしてのピロール誘導体 |
| WO2013005153A1 (en) | 2011-07-05 | 2013-01-10 | Lupin Limited | Biaryl derivatives as nachr modulators |
-
2013
- 2013-02-22 CA CA2866015A patent/CA2866015A1/en not_active Abandoned
- 2013-02-22 WO PCT/IB2013/051455 patent/WO2013132380A1/en not_active Ceased
- 2013-02-22 EP EP13711972.3A patent/EP2822946A1/en not_active Withdrawn
- 2013-02-22 IN IN1756MUN2014 patent/IN2014MN01756A/en unknown
- 2013-02-22 US US14/379,134 patent/US9388196B2/en not_active Expired - Fee Related
- 2013-02-22 NZ NZ629453A patent/NZ629453A/en not_active IP Right Cessation
- 2013-02-22 SG SG11201405239WA patent/SG11201405239WA/en unknown
- 2013-02-22 AU AU2013229177A patent/AU2013229177B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013132380A1 (en) | 2013-09-12 |
| US20150291617A1 (en) | 2015-10-15 |
| SG11201405239WA (en) | 2014-09-26 |
| NZ629453A (en) | 2016-04-29 |
| US9388196B2 (en) | 2016-07-12 |
| AU2013229177B2 (en) | 2017-03-23 |
| EP2822946A1 (en) | 2015-01-14 |
| CA2866015A1 (en) | 2013-09-12 |
| AU2013229177A1 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01756A (enExample) | ||
| PH12013501727A1 (en) | Heteroaryl derivatives as alpha7 nachr modulators | |
| PH12019500830A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| MX344696B (es) | Derivados de pirrol como moduladores de los receptores de acetilcolina nicotinicos para su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer y la enfermedad de parkinson. | |
| PH12014502341A1 (en) | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments | |
| PH12015500376B1 (en) | Novel bicyclic pyridinones | |
| EA201490807A1 (ru) | Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1 | |
| IN2014MN02106A (enExample) | ||
| MX2009012168A (es) | Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta. | |
| MX2013008431A (es) | Antagonista del receptor de mineralocorticoides. | |
| SI2875011T1 (en) | 5-HT3 receptor antagonists | |
| WO2013188283A8 (en) | Topical ophthalmological pharmaceutical composition containing sunitinib | |
| PH12014502541A1 (en) | 5-amino [1,4] thiazines as bace 1 inhibitors | |
| TN2013000533A1 (en) | Topical ophthalmological pharmaceutical composition containing regorafenib | |
| MY193041A (en) | Novel fused imidazobenzothiazole compounds | |
| IN2013DN02555A (enExample) | ||
| WO2014014794A3 (en) | Mineralocorticoid receptor antagonists | |
| MY157629A (en) | Fused thiazolo and oxazolo pyrimidinones | |
| MX2016010745A (es) | Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina. | |
| MX2015007488A (es) | Composicion farmaceutica oftalmologica topica que contiene regorafenib. | |
| MX2018014165A (es) | Compuestos heterociclicos utiles como agentes antibacterianos y metodo de produccion. | |
| NZ600536A (en) | Bicyclic compounds as alpha4 beta2 nicotinic acetylcholine receptor ligands | |
| MX2014000855A (es) | Moduladores receptores de glucagon de quinolinilo. | |
| GEP20156227B (en) | Azabicyclo[3.1.0]hex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same | |
| TN2013000345A1 (en) | Heteroaryl derivatives as alpha7 nachr modulators |